- With a CHMP decision expected Friday, Wells Fargo is out with some interesting commentary on regulatory data protection for Biogen's (BIIB +0.6%) Tecfidera in Europe.
- "Given the possibility that BIIB might not launch in EU without data protection, the threat of withholding an important treatment option for MS in Europe could raise political pressure on regulators from the patient and physician communities to assign the drug NAS status," analyst Brian Abrahams says, suggesting the company has quite a bit of leverage in the process.
- According to Deutsche's Robyn Karnauskas, the difference between
EU exclusivity and no EU exclusivity is around $12/share — price target of either $250 or $238, respectively.
- Karnauskas recently said that without an EU launch, BIIB's target price is $225.